Information Provided By: 
Fly News Breaks for February 22, 2019
ZGNX
Feb 22, 2019 | 07:30 EDT
Guggenheim analyst Yatin Suneja initiated Zogenix with a Buy rating and $70 price target, citing his view that lead clinical asset Fintepla has shown "impressive" antiepileptic properties with a favorable risk-benefit profile. Although Dravet Syndrome is likely to be the first approved indication, Suneja believes the drug's full potential lies in its applicability across a variety of treatment resistant seizure disorders, he tells investors.
News For ZGNX From the Last 2 Days
There are no results for your query ZGNX
